Imaging of lumps and bumps in the nose: a review of sinonasal tumours

Sudip Das* and Claudia F E Kirsch†

*LAS Otolaryngology, Leicester Royal Infirmary, Leicester, UK; †Department of Neuroradiology, Barts and the Royal London NHS Trust, London, UK

Corresponding address: C Kirsch MD, Department of Neuroradiology, Royal London Hospital, Whitechapel Road, E1 1BB, London, UK. E-mail: tr1386@aol.com

Date accepted for publication 7 September 2005

Abstract

Sinonasal disease is one of the most common clinical head and neck pathologies. The majority of sinonasal pathology is inflammatory with neoplasms comprising approximately 3% of all head and neck tumours. Although sinus tumours are rare, they portend a poor prognosis, often due to advanced disease at diagnosis. Like most neoplasms, early detection improves prognosis, therefore clinicians and radiologists should be aware of features separating tumours from inflammatory sinus disease. This article reviews the anatomy, clinical features, imaging findings, treatment and histopathology of selected sinonasal tumours. Benign neoplasms reviewed include osteoma, inverting papilloma, and juvenile nasal angiofibroma. Malignant neoplasms reviewed include squamous cell carcinoma, the minor salivary gland tumour, adenoid cystic carcinoma, adenocarcinoma, melanoma, lymphoma, and olfactory neuroblastoma (esthesioneuroblastoma).

Keywords: Sinuses; carcinoma; computed axial tomography (CT); magnetic resonance imaging (MRI).

Introduction

The sinonasal cavity extends from the nostrils to the posterior nasal septum ending posteriorly in the nasopharynx. The nasal cavity floor is the hard palate, also the roof of the mouth. Three turbinate bones project medially from the lateral walls. Four aerated paranasal sinuses: maxillary, ethmoid, frontal and sphenoid surround the nasal cavity. Ethmoidal sinuses create the superior lateral and medial nasal cavity walls with bilateral maxillary antra forming the inferior lateral margins. The superior maxillary sinus forms the orbital floor, disrupted by the infraorbital groove containing the infraorbital nerve. The frontal sinuses anteriorly contribute to the orbital roofs and the sphenoid sinus posteriorly is the nasopharynx roof. Classically, benign neoplasms expand and remodel bone and aggressive malignancies destroy and invade adjacent tissues with ill-defined margins. These rules however, may be broken in sinonasal imaging. Computed tomography (CT) has superior bony definition while magnetic resonance imaging (MRI) better distinguishes tumour versus retained secretions. MRI gives superior soft tissue delineation in the adjacent infratemporal fossa, masticator space, and in evaluation of perineural, intraorbital and intracranial spread[1].

Staging for sinus cancer is via the T-system noted below:

- **T1**: tumour confined to antral mucosa with no bone erosion or destruction
- **T2**: tumour with erosion or destruction infrastructure, hard palate, and/or middle nasal meatus
- **T3**: tumour invasion into skin of cheek, posterior maxillary sinus wall, floor of medial orbital wall, anterior ethmoid sinus
- **T4**: massive tumour with invasion of cribiform plate,

This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI provided to locate the paper.
posterior ethmoids, sphenoid, nasopharynx, pterygoid plates, base of skull or orbit.

Additional imaging considerations include determination of tumour margins for assessing resectability, surgical approach and radiation therapy fields. Imaging is vital in distinguishing tumour from infection, retained secretions, and granulation scar tissue. The majority of malignant sinonasal cavity tumours are epithelial in origin with approximately 80% squamous cell carcinomas[2]. Because these cellular tumours have little water content, they demonstrate low to intermediate signal intensity on MRI images. Ten percent of sinonasal tumours are lymphomas or olfactory neuroblastomas, sarcomas, and fibrous histiocytomas. These cellular carcinomas also display MRI characteristics similar to carcinomas found elsewhere. The final 10% of tumours arise from minor salivary glands, and reflect their diverse histology containing either serous or mucinous elements. The majority of tumours on MRI T2W sequences have intermediate signal intensity compared to inflammatory tissue which has increased signal intensity[3]. Approximately 5% of sinonasal tumours of minor salivary gland origin may have increased T2-signal, and a biopsy may be needed to determine if a tumour is present.

**Figure 1** Coronal CT scan, bone windows, soft tissue mass obstructing the right osteomeatal unit and complete opacification of the right maxillary antrum. Bony erosion noted along the right maxillary medial wall.

**Benign tumours**

**Osteoma**

**Clinical features**

The presentation of osteomas depends on their location, commonly originating in the frontal sinuses[4]. These benign tumours are usually incidental findings on imaging. They may block the fronto-ethmoidal recess giving rise to unilateral headaches or a mucocele, which may expand intracranially, causing pressure symptoms, personality changes and pneumatoceles or intraorbitally, causing proptosis and diplopia[5,6]. Ethmoidal osteomas invariably spread intraorbitally causing orbital symptoms and occasional nasal obstruction, epiphora and facial deformity[7]. Rarely, osteomas may present in the maxillary and sphenoid sinuses[8].

**Imaging**

Osteomas on CT scanning are hyperdense bony masses protruding into the sinus cavity. Because of the dense compact bone, they are poorly seen on MRI.

**Treatment**

Only osteomas causing symptoms are removed surgically. They are difficult removals due to the challenge of obtaining adequate exposure, spawning a variety of surgical approaches. The osteoplastic frontal sinus approach with coronal incision is preferred for best aesthetic results for frontal sinus osteomas[9]. Ethmoidal osteomas can be removed with a mid-facial degloving or a lateral rhinotomy combined with orbital exposure and medial maxillectomy. Endonasal approach with stereotactic localisation, is used increasingly for excision[10,11]. Treatment is individualised and close follow-up is needed to rule out recurrence[12].

**Pathology**

Tumour origin is ascribed to embryologic tissue maldevelopment, trauma, or infection. The tumours are hard and lobulated with an ivory-like appearance, often mixed with a coarse granular component. The bone is compact or cancellous, with vascular or connective tissue components[4].

**Inverted papilloma**

**Clinical features**

Inverted papilloma is a benign tumour classically arising in the lateral nasal wall near the middle turbinate[13]. The tumour is predominant in males, and is staged according to disease extent and surgical planning[14,15]. Tumours are often unilateral and have a pernicious ability to recur after partial resection. They are unfortunately associated with squamous cell carcinomas, with reports varying from 2% to 15%[20,21].

**Imaging**

By location, tumours arise from the nasal cavity lateral walls and septum. It is virtually impossible to distinguish
benign versus malignant papilloma on imaging as both have intermediate signal on T2W MRI and solid enhancement. Associated bone loss is often a sign of aggressiveness either neoplastic or in some cases due to infection or inflammation (Fig. 1).

**Figure 2** Axial CT bone windows of a juvenile nasal angiofibroma (JNA) completely opacifying the left nasal cavity, enlarging the left pterygopalatine fossa with extension to the left foramen rotundum and vidian canals.

**Treatment**

Traditional techniques such as Caldwell-Luc and conservative trans-nasal ethmoidectomy or sphenethmoidectomy have given way to endoscopic surgery as an effective treatment for inverted papillomas\[16\]. Proper patient selection, meticulous use of sub-periosteal dissection, and regular follow-up are key for success\[17–19\]. Radiation therapy may be considered in incompletely resectable lesions, recurrent tumours, and tumours associated with malignancy\[20\].

**Pathology**

Inverted papillomas have marked patchy squamous metaplasia in ductal and surface epithelium and numerous microcysts containing macrophages in the epithelia. Low-grade squamous carcinoma is difficult to distinguish from inverted papilloma on imaging and biopsy with histopathology is the best option\[21\].

**Juvenile nasopharyngeal angiofibroma**

**Clinical features**

Juvenile nasopharyngeal angiofibroma (JNA) is a histologically benign, locally invasive tumour found primarily in the pubescent male\[22\]. Patients present with recurrent epistaxis and nasal obstruction\[23\]. Two constant features include: (1) mass in posterior nasal cavity and pterygopalatine fossa; (2) erosion of bone behind the sphenopalatine foramen extending to the upper medial pterygoid plate\[24\]. Chandler’s, Fisch’s and Radkowski’s staging are based on tumour extent and spread and demarcate surgical approaches and prognosis. Grade 1 is confined to nasopharynx, Grade 2 is spread into pterygopalatine fossa or masticator space, Grade 3 is spread intraorbitally or intracranially.

**Figure 3** Coronal T2W, MRI of same patient as in Fig. 2, JNA demonstrating multiple small flow voids in the vascular tumour and the utility of MRI in distinguishing tumour from retained secretions in the left maxillary antrum.

**Imaging**

Characteristics on either CT or MRI include bowing of the posterior maxillary antrum anteriorly, enlargement of pterygopalatine fossa with bone erosion posterior to the sphenopalatine foramen extending towards the medial pterygoid plate\[24\] and on post-contrast studies dense enhancement with the mass predominately fed by the ipsilateral internal maxillary artery and small ascending pharyngeal artery branches (Figs 2–4).

**Treatment**

Surgical resection is the preferred treatment. Preoperative embolisation may significantly reduce operative blood loss and the need for transfusions\[25\]. Adjunctive therapy includes oestrogens, cryotherapy and arterial ligation. Radiotherapy is contraindicated except in select cases\[26\]. Lesions limited to nasal and nasopharyngeal cavities with sphenoid and ethmoid invasions can be removed endoscopically\[27–29\]. Larger tumours—
Radkowski’s stage III and above—require external approaches, including trans-palatal, mid-facial degloving, lateral rhinotomy, trans-zygomatic and facial lowering by Le Fort I. Intracranial extension requires a combined intra- and extracranial approach. Additional radiotherapy is reserved for incomplete resections\cite{22,30,31}.

Pathology
The tumours show a characteristic zonal organisation of a sub-epithelial myxoid-fibrous zone and a proliferative capillary fibroblastic cambium layer made of capillary/vascular channels and fibrous components in varying amounts. The latter exhibits a changing cellularity and fibre content. Large areas of hyalinisation predominate centrally, with fibrous tissue prevailing in older lesions\cite{32}.

Figure 4  Same patient as in Figs 2 and 3. Cerebral angiogram demonstrating marked vascularity of the JNA with feeding vessels from the left internal maxillary artery and branches of the left ascending pharyngeal artery.

Malignant tumours

Squamous cell carcinoma

Clinical features
Squamous cell carcinoma (SCCA) is the commonest malignant tumour of the sinonasal cavity\cite{33}. They are more frequent in males\cite{34}. Nickel workers are particularly susceptible to SCCA of the sinonasal cavity\cite{42}. Like other nasal malignancies, they present as a nasal mass with symptoms of obstruction, discharge and bleeding and facial swelling\cite{36}. An SCCA may present as a non-healing ulcer inside the nose. Most series identify the maxillary sinus or nasal cavity as the most common site of origin\cite{33–36}. Because of late presentation, the exact site of origin is often unidentifiable. Delayed presentation is often due to initial non-specific symptoms, with more than half being T3 or T4\cite{34,36}.

Imaging
Most SCCAs are in the maxillary sinuses. On MRI, most SCCAs are hypointense on T2W images and heterogeneous with solid enhancement, as opposed to the uniform homogenous appearance of secretions which have peripheral rim enhancement of the sinus mucosa. Other tumours including benign inverting papillomas or neoplastic lymphomas may have similar imaging characteristics. An important radiographic finding for malignancies is bone destruction, best seen on CT and noted on initial exams in approximately 80% of sinonasal SCCAs. Staging follows TNM classification, with Ohngren’s line extending from the orbital medial canthus to the mandibular angle, dividing the inferior anterior margins from the superior posterior margins.

Figure 5  Axial CT post-contrast soft tissue windows in a patient with adenoid cystic carcinoma (ACC) extending throughout the left nasal cavity, left maxillary sinus and left pterygoid fossa with enlargement and loss of fat in the left pterygopalatine fossa and left infratemporal fossa. Perineural tumour extension is expected along the V2 branches in pterygopalatine fossa, infraorbital nerve and foramen rotundum.

Treatment
In resectable tumours, the optimal treatment is combined surgery and radiotherapy\cite{35–38}. Adjunctive chemotherapy is used for larger tumours. Histology, localisation and nodal involvement are significant prognostic factors for locoregional control and survival\cite{33}. Orbital and neural invasion significantly affected local control\cite{36}. Local failure remains the dominant cause for poor outcome\cite{36}. Cervical metastases developing subsequent to initial
therapy is associated with poor survival rates\cite{40,42}. The 5-year corrected survival for sinonasal SCCA is 35\%\cite{41}.

Pathology

Squamous cell carcinoma arises from atypical epidermal cells resulting in a hypertrophic nodule or a non-healing ulcer. Breach of the basal membrane converts it from an in situ to an invasive carcinoma.

Figure 6  Coronal CT post-contrast same patient as Fig. 5 with ACC. Demonstrating tumour throughout the left nasal cavity with bony destruction of the left maxillary sinus, loss of fat in the left infratemporal fossa and extension in the left orbital apex along the V2 division.

Adenoid cystic carcinoma

Clinical features

Sinonasal adenoid cystic carcinoma (ACC) arises from minor salivary glands as an aggressive neoplasm with a high incidence of local recurrence and distant metastasis, regardless of treatment modality\cite{43}. It presents in females twice as much as males\cite{45,46}, while cervical lymphadenopathy is rare\cite{47}. Local spread in ACC may occur by lysis of adjacent bone and/or perineural and peri-vascular spread\cite{48}. Local recurrence is more common in incomplete excision or with perineural spread\cite{47}. Metastatic development is independent of local recurrence. Bony metastases are more rapidly aggressive than pulmonary metastases, which may remain asymptomatic\cite{47}.

Imaging

Because of the varied histology related to cell density, cysts, tubular or cribiform patterns, the signal intensity on MRI sequences can vary widely. Adenoid cystic carcinoma has a propensity for perineural spread. A careful imaging assessment of trigeminal nerve branches, especially within the pterygopalatine fossa, is essential to evaluate for intracranial extension. Key signposts include a mass with loss of adjacent fat, and perineural enhancement suggestive of perineural spread along routes within foramen rotundum and the infraorbital fissure (V2), and foramen ovale (V3). It is important to remember that nearly all neoplasms, not just adenoid cystic can also spread perineurally (Figs 5–8).

Figure 7  Same patient as in Figs 5 and 6. Coronal T1 MRI without contrast of ACC filling the left nasal cavity and left maxillary sinus with extension and loss of fat in the left infratemporal fossa. Perineural tumour spread again noted along V2 in the infraorbital foramen.

Treatment

Though the 5-year survival may be better than other sinonasal cancers, most cases are ultimately fatal, with long disease-free intervals being observed. A combination of surgery and post-operative radiotherapy offers the best chance for disease control compared with the either treatment modality alone\cite{43,45,48}.

Pathology

Tumours of ‘massive’ or solid or adenoid cystic histological type carry a poorer prognosis than the cribiform or mucoepidermoid type\cite{44,45,48}.

Adenocarcinoma

Clinical features

Sinonasal adenocarcinomas are unusual tumours with variable clinical courses. Nasal obstruction is the most common presentation. Age, tumour grade and intracranial extension are associated with overall survival
and death from disease\textsuperscript{[49]}. The relationship between ethmoidal adenocarcinomas and ‘hard wood’ dust exposure is well established. Duration and average level contribute independently to the overall elevated risk. In addition formaldehyde exposure in the leather industry increases the risks for developing sinonasal adenocarcinoma\textsuperscript{[50]}.

\textbf{Imaging}

Adenocarcinomas tend to occur in the ethmoid sinus. On MRI, the tumour usually has a slightly hypointense signal on T2W images. Occasional masses may show increased signal intensity as seen in adenoid cystic tumours (Figs 9–11).

\textbf{Treatment}

Treatment for nasal adenocarcinoma varies widely depending on tumour stage and metastasis. Low-grade variants of nasal adenocarcinomas are associated with a favourable prognosis and can be treated with less aggressive therapy\textsuperscript{[49]}. Surgical excision is the standard treatment. Either a trans-facial approach (lateral nasal and degloving) or a cranio-facial approach may be used, depending on the site and tumour extent\textsuperscript{[51]}. Post-operative radiotherapy is used adjunctively for better tumour free survival\textsuperscript{[52]}. Some authors claim a combination of surgical debulking and repeated topical chemotherapy provide equally good results\textsuperscript{[53]}. Extensive tumours are palliated with low-dose radiotherapy\textsuperscript{[52]}.

\textbf{Pathology}

Adenocarcinomas are subdivided into well, moderately, and poorly differentiated adenocarcinomas, and mucinous adenocarcinomas. Patients with mucinous and poorly differentiated adenocarcinomas have significantly shorter disease-free intervals and survival rates than those with well differentiated and moderately differentiated adenocarcinomas\textsuperscript{[54]}.

\textbf{Lymphoma}

\textbf{Clinical features}

Sinonasal lymphomas are relatively uncommon, representing less than 1\% of all head and neck malignancies. They are predominantly non-Hodgkin’s lymphomas (NHL)\textsuperscript{[55]}. Currently, two distinct subgroups are recognised, characterised by phenotype, location, prognosis, and treatment. Lymphomas of the B-cell phenotype are the most frequent sinonasal tumours. They are less aggressive with a better prognosis. The rarer T/NK-cell lymphomas are mostly found in the nasal cavity; though in South America and Asia, a T-cell phenotype predominates\textsuperscript{[56]}. These are aggressive with a worse prognosis\textsuperscript{[55]}. Burkitt’s lymphoma (BL) is a high-grade B-cell non-Hodgkin’s lymphoma, associated with Epstein Barr virus usually involving the maxilla and facial bones in the endemic African variant; head and neck lesions in non-endemic BL are rare\textsuperscript{[57]}. The disease occurs in a predominantly male elderly population, except BL which mainly affects children\textsuperscript{[56]}.
Imaging of sinonasal tumours 173

Figure 10  Same patient as in Fig. 9. MRI T1W post-gadolinium of adenocarcinoma showing heterogeneous enhancement of tumour throughout the right sinonasal cavity and maxillary sinus.

Low grade lymphomas present with a sinonasal mass associated with obstructive symptoms. High grade lymphomas are more likely to present with aggressive symptoms, including non-healing ulcer, cranial nerve manifestations, facial swelling, epistaxis, or pain. High grade B-cell lymphomas tend to present with soft tissue or osseous destruction, particularly of the orbit with associated proptosis. T-cell lymphomas are associated with nasal septal perforation and/or destruction.

Imaging

In the sinonasal cavity, the majority of lymphomas are non-Hodgkin’s histiocytic lymphoma. The tumours are bulky masses with intermediate signal intensity on MRI images with moderate enhancement. The lesions remodel and may erode adjacent bone. Tumours are usually within the nasal fossa and maxillary sinus, and less commonly in the ethmoids and very rarely in the sphenoid and frontal sinuses (Figs 12–15).

Pathology

The nasal type of extranodal NK/T-cell lymphoma has a characteristic histologic pattern, which is angio-centric, angio-invasive and angio-destructive and a thorough immuno-histological study should always be conducted in these cases.

Melanoma

Clinical features

Melanomas in the sinonasal cavity can be similar in appearance to other malignant tumours when they are amelanotic. Patients present with epistaxis and nasal obstruction. A significant proportion arises from the septum.

Imaging

The nasal septum requires close inspection, as this is where melanoma most commonly occurs; the next most common site is the turbinates. Melanomas containing melanin have a paramagnetic effect shortening the T1 and T2 relaxation times, creating increased signal on T1W images and decreased signal on T2W scans. Amelanotic tumours may demonstrate the reverse, with increased signal on T1 and high signal on T2W images. Tumours may have hemorrhagic components also altering the signal intensities.
Figure 12  Axial CT bone windows in patient with olfactory neuroblastoma with tumour extension through the right lamina papyracea causing lateral bowing of the right medial rectus muscle.

Figure 13  Same patient as in Fig. 12; note the right and left sides are reversed on this coronal image. The olfactory neuroblastoma again extends intraorbitally through the lamina papyracea as well as through the cribriform plate.

Figure 14  Sagittal T1W post-gadolinium contrast MRI; same patient as Figs 12 and 13. The olfactory neuroblastoma extends cephalad through the cribriform plate into the anterior cranial fossa and is shown with a cystic component superiorly.

Pathology

Histologically, tumours are composed of a variety of cell types, epithelioid, spindled, undifferentiated, frequently arranged in a peritheliomatous distribution. Immuno-histochemical studies are necessary if amelanotic type is suspected and aid in diagnosis of carcinoma, lymphoma, sarcoma, and olfactory neuroblastoma. Positive reactions for S-100 protein, tyrosinase, HMB-45, melan A and microphthalmia transcription factor indicate melanoma.

Olfactory neuroblastoma

Clinical features

Olfactory neuroblastomas originate from olfactory epithelium in the upper part of the nasal cavity. The common presenting symptoms include hyposmia, anosmia, nasal congestion, facial pain and epistaxis, headache and personality changes if the frontal lobe is affected. Rarely, ectopic tumour hormone secretion gives rise to SIADH or Cushing’s Syndrome. Orbit extension may cause exophthalmos, ophthalmoplegia and or visual loss. Staging predicts prognosis; in group A, tumour is limited to the nasal cavity; in group B, the tumour is localised to the nasal cavity and para-nasal sinuses; and in group C, the tumour extends beyond the nasal cavity and para-nasal sinuses.
**Imaging**

On CT and MRI, the tumour is often centred at the cribiform plate. The mass may be homogenous or have areas of inhomogeneity and moderate enhancement. On T1W images the tumour is decreased in signal compared to brain parenchyma and may be isointense or increased in signal relative to brain on T2W scans. Important associated imaging characteristics include cysts along the superior tumour margins especially within the anterior cranial fossa intracranially.

**Treatment**

Multi-modality treatment involving surgery, chemotherapy and radiotherapy appears highly effective in preventing relapse in advanced ENB\(^7\).\(^{12}\). The preferred surgical approach is a cranio-facial resection\(^7\).\(^2\). Large tumours are considered for pre-operative chemotherapy and post-operative radiotherapy\(^7\).\(^3\).

**Pathology**

Histologically, the tumour contains epithelial nests of small round cells and small short spindle cells surrounded by a net of fibrous connective tissue. Immuno-histochemistry is essential for diagnosis\(^7\).\(^3\). Neuron-specific enolase (NSE) is uniformly distributed throughout tumour cell clusters within tumour nodules while S-100 protein is distributed at the periphery of tumour cell nests. Anti-synaptophysin, microtubule-associated protein-2, and class III beta-tubulin isotype are present in most esthesioneuroblastomas.

**Conclusion**

Although rare, sinonasal tumours often have a poor prognosis due to a delay in diagnosis. This article reviews the salient clinical features, imaging, treatment and pathology of selected benign and malignant neoplasms within the nasal cavity, in order to help clinicians and radiologists better distinguish between sinonasal inflammatory disease and neoplasms.

**References**

[1] Som P. Tumors and tumorlike conditions of the sinonasal cavity. In: Head and Neck Imaging, 2nd ed. Som P, Bergeron RT, eds. St. Louis: Mosby-Year Book, 1990: 169–227.
[2] Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1992; 42: 19–38.
[3] Som PM, Dillon WP, Sze G et al. Benign and malignant sinonasal lesions with intracranial extension: differentiation with MR imaging. Radiology 1989; 172: 763–6.
[4] Namdar I, Edelstein DR, Huo J, Lazar A, Kimmelman CP, Soletic R. Management of osteomas of the paranasal sinuses. Am J Rhinol 1998; 12: 393–8.
[5] Rappaport JM, Attia EL, Pneumocephalus in frontal sinus ostoma: a case report. J Otolaryngol 1994; 23: 430–6.
[6] Hehar SS, Jones NS. Fronto-ethmoid ostoma: the place of surgery. J Laryngol Otol 1997; 111: 372–5.
[7] Osma U, Yaldiz M, Tekin M, Topcu I. Giant ethmoid ostoma with orbital extension presenting with epiphora. Rhinology 2003; 41: 122–4.
[8] Boysen M. Osteomas of the paranasal sinuses. J Otolaryngol 1978; 7: 366–70.
[9] Schick B, Steigerwald C, el Rahman el Tahan A, Draf W. The role of endonasal surgery in the management of frontoethmoidal osteomas. Rhinology 2001; 39: 66–70.
[10] Selva D, Chen C, Wormald PJ. Frontoethmoidal ostoma: a stereotactic-assisted sino-orbital approach. Ophthal Plast Reconstr Surg 2003; 19: 237–8.
[11] Brodiss BN, Morgan CE, Sillers MJ. Endoscopic resection of fibro-osseous lesions of the paranasal sinuses. Am J Rhinol 1999; 13: 111–6.
[12] London SD, Schlosser RJ, Gross CW. Endoscopic management of benign sinonasal tumors: a decade of experience. Am J Rhinol 2002; 16: 221–7.
[13] Savy L, Lloyd G, Lund VJ, Howard D. Optimum imaging for inverted papilloma. J Laryngol Otol 2000; 114: 891–3.
[14] Outzen KE, Grontved A, Jorgensen K, Clausen PP. Inverted papilloma of the nose and paranasal sinuses: a study of 67 patients. Clin Otolaryngol Allied Sci 1991; 16: 309–12.
[15] Krouse JH. Development of a staging system for inverted papilloma. Laryngoscope 2000; 110: 965–8.
[16] Pasquini E, Sciarella V, Farneti G, Modugno GC, Ceroni AR. Inverted papilloma: report of 89 cases. Am J Otolaryngol 2004; 25: 178–85.
[17] Stankiewicz JA, Gazerg SJ. Endoscopic surgical treatment of nasal and paranasal sinus inverted papilloma. Otolaryngol Head Neck Surg 1993; 109: 988–95.
[18] Tomonuki D, Castelnuovo P, Pagella F et al. Different endoscopic surgical strategies in the management of inverted papilloma of the sinonasal tract: experience with 47 patients. Laryngoscope 2004; 114: 193–200.
[19] Lee TJ, Huang SF, Lee LA, Huang CC. Endoscopic surgery for recurrent inverted papilloma. Laryngoscope 2004; 114: 106–12.
Cullen MJ, Cusack DA, O’Brien DS, Devlin JB, Keely A, Lyons TA. Neurosecretion of arginine vasopressin by an olfactory neuroblastoma causing reversible syndrome of antidiuresis. Am J Med 1986; 81: 911–6.

Yu J, Koch CA, Patsalides A et al. Ectopic Cushing’s syndrome caused by an esthesioneuroblastoma. Endocr Pract 2004; 10: 119–24.

Tamase A, Nakada M, Hasegawa M, Shima H, Yamashita J. Recurrent intracranial esthesioneuroblastoma outside the initial field of radiation with progressive dural and intra-orbital invasion. Acta Neurochir (Wien) 2004; 146: 179–82.

Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37: 1571–6.

Dias FL, Sa GM, Lima RA et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129: 1186–92.

Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 2003; 11: 112–8.

Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future? Laryngoscope 2003; 113: 502–7.

Frierson HF Jr, Ross GW, Mills SE, Frankfurter A. Olfactory neuroblastoma. Additional immunohistochemical characterization. Am J Clin Pathol 1990; 94: 547–53.